[Drug therapy of initial open-angle glaucoma]

Area of Science:

• Ophthalmology
• Pharmacology

Background:

• Open-angle glaucoma is a leading cause of irreversible blindness.
• Effective long-term management is crucial for preserving vision.
• Initial glaucoma requires a systematic and pathogenetically grounded treatment strategy.

Purpose of the Study:

• To analyze the efficacy of long-term medical treatment for initial open-angle glaucoma.
• To compare the effectiveness of different hypotensive medications.
• To evaluate the impact of combined therapy on intraocular pressure and disease stabilization.

Main Methods:

• Retrospective analysis of 86 patients with initial open-angle glaucoma.
• Administration of various hypotensive medications including miotics, sympathomimetics, beta-blockers, and carbonic anhydrase inhibitors.
• Inclusion of vascular-correcting agents (angioprotectors, cavinton, rheopolyglucin) in treatment regimens.

Main Results:

• Miotics achieved intraocular pressure regulation in 30% of cases; sympathomimetics in 53%.
• Beta-blockers demonstrated the most effective long-term intraocular pressure regulation.
• Systematic, pathogenetically grounded treatment led to glaucomatous process stabilization in 88% of patients.

Conclusions:

• Beta-blockers are highly effective for long-term intraocular pressure management in initial open-angle glaucoma.
• A comprehensive, individualized medical treatment approach significantly improves disease stabilization.
• Targeted therapy addressing both intraocular pressure and vascular disturbances is key to successful glaucoma management.